Application of [18F]D3FSP positron imaging agent in the diagnosis and efficacy evaluation of Alzheimer's disease

To study the clinical application value of targeting amyloid positron imaging agent [18F]D3FSP ([18F]D3-AV45)

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100054488

Enrollment

Unknown

Registered

2021-12-18

Start date

2021-04-15

Completion date

Unknown

Last updated

2022-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's disease (AD)

Interventions

Gold Standard:Clinical diagnostic criteria for Alzheimer's disease

Index test:Amyloid deposits

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with confirmed AD or suspected AD; 2. The general condition of the patient is acceptable and can tolerate PET examination; 3. A certain number of healthy volunteers.

Exclusion criteria

Exclusion criteria: 1. Those who have fertility requirements within half a year and cannot bear the risk of radiation; 2. Those who have allergic reactions to radiotracers ([18F]D3FSP) or similar chemical structure substances.

Design outcomes

Primary

Measure	Time frame
normalized uptake ratio;	—

Countries

China

Contacts

Public ContactWang Xinlu

71Lu@163.com+86 13226616001

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026